Shortly after Amgen unveiled its $1.9 billion alliance with Generate Biomedicines aimed initially at five drug molecules, Sanofi has announced a big expansion of its longstanding partnership with ...

The drugmaker looks to rein in how it gives discounts in a federal program designed to help hospitals that serve low-income ...

Sanofi plans to phase in its own rebate model for 25 drugs — including anti-inflammatory injectable Dupixent, one of the top ...

Sanofi is the third company - along with J&J and Eli Lilly - to attempt to change the way it pays for medicines under the ...

The battle over prescription drug discounts offered to hospitals under a federal program escalated as Sanofi became the third ...

Two months after Sanofi completed construction in France of its innovative Modulus vaccine and biologics plant—which can be ...

With several high-profile manufacturing outlays already in the books in Europe this year, Sanofi is returning to the bloc in ...

Regeneron Pharmaceuticals Inc. claims that a partner has broken a collaboration deal by refusing to reveal side deals for marketing ...

Hudson says many CEOs are scared of AI, comparing it to The Terminator’s John Connor traveling back in time to stop the rise ...

French drugmaker Sanofi plans to change its policy on how it gives discounts to certain U.S. hospitals that serve low-income ...

The US Food and Drug Administration (FDA ... Zaltrap, developed by Sanofi and Regeneron Pharmaceuticals, will compete with Roche Holding AG’s Avastin (bevacizumab) and Bristol-Myers Squibb ...

Sanofi gets rated buy today, agreeing with bullish ratings from the Wall Street and SA analysts' consensus. With a diverse drug portfolio and a robust pipeline of future drugs to market ...